Comera Life Sciences Holdings, Inc.
CMRA
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -41.98% | 114.79% | 312.28% | 112.96% | 167.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.98% | 114.79% | 312.28% | 112.96% | 167.54% |
| Cost of Revenue | -31.15% | 2.75% | 161.80% | 29.56% | 26.03% |
| Gross Profit | -45.80% | 180.91% | 444.09% | 207.56% | 341.62% |
| SG&A Expenses | -18.54% | -58.49% | 20.68% | -26.99% | 216.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.21% | -56.42% | 13.56% | -20.61% | 176.62% |
| Operating Income | 14.92% | 62.74% | -1.95% | 25.44% | -177.49% |
| Income Before Tax | 30.00% | 84.46% | 13.83% | -46.37% | -236.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.00% | 84.46% | 13.83% | -46.37% | -236.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.00% | 84.46% | 13.83% | -46.37% | -236.74% |
| EBIT | 14.92% | 62.74% | -1.95% | 25.44% | -177.49% |
| EBITDA | 15.03% | 63.17% | -1.82% | 25.73% | -180.78% |
| EPS Basic | 50.91% | 93.14% | 96.63% | 98.34% | 96.89% |
| Normalized Basic EPS | 51.50% | 93.39% | 96.75% | 99.21% | 96.97% |
| EPS Diluted | 50.91% | 93.14% | 96.63% | 98.34% | 96.89% |
| Normalized Diluted EPS | 51.50% | 93.39% | 96.75% | 99.21% | 96.97% |
| Average Basic Shares Outstanding | 44.24% | 135.25% | 2,549.42% | 8,994.93% | 11,012.34% |
| Average Diluted Shares Outstanding | 44.24% | 135.25% | 2,549.42% | 8,994.93% | 11,012.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |